Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC

NCT07554846 | Not Yet Recruiting Phase 3

• 1 other identifier: NSCLC-IIT-JS001-P04
• Study Type: interventional
• Target: 759
• Locations: 1 country
• Sites: 1

Brief Summary

This is a randomized, open-label, multi-center Phase III clinical study aimed at head-to-head evaluating the clinical efficacy of three immunotherapy strategies, namely perioperative immunotherapy, neoadjuvant immunotherapy, and adjuvant immunotherapy using Toripalimab, in patients with resectable stage II-IIIA non-small cell lung cancer (NSCLC) without EGFR/ALK mutations. This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1030.

Conditions

Resectable Stage II-IIIa NSCLC

Keywords

lung cancer; immunotherapy

Outcome Measures

Primary Outcomes (1)

• 3-year events-free survival (EFS) rate

  It is defined as the percentage of the total number of individuals in the analysis dataset who, from randomization to the first recorded event, die due to disease progression leading to inoperability, distant metastatic lesions, local recurrence, or any other reason within 3 years.

  From randomization up to 3 years after randomization

Study Arms (3)

Perioperative immunotherapy

EXPERIMENTAL

After randomization, patients will receive neoadjuvant treatment with three cycles of Toripalimab combined with platinum-based doublet chemotherapy, one cycle per 3 weeks and the drug administered on the first day of each cycle. Radical surgery will be performed within 4-6 weeks after completing the three cycles of neoadjuvant treatment. Subjects who have undergone radical surgery will receive one cycle of adjuvant treatment with Toripalimab combined with platinum-based doublet chemotherapy post-surgery, followed by 13 cycles of maintenance treatment with Toripalimab, one cycle per 3 weeks and the drug administered on the first day of each cycle

Drug: Peroperative immunotherapy

Neoadjuvant immunotherapy

ACTIVE COMPARATOR

After randomization, patients will receive neoadjuvant treatment with three cycles of Toripalimab combined with platinum-based doublet chemotherapy, one cycle per 3 weeks and the drug administered on the first day of each cycle. Radical surgery will be performed within 4-6 weeks after completing the three cycles of neoadjuvant treatment. Subjects who have undergone radical surgery will selectively receive adjuvant chemotherapy with or without radiation therapy post-surgery

Drug: Neoadjuvant immunotherapy

Adjuvant immunotherapy

ACTIVE COMPARATOR

After randomization, subjects will undergo radical surgery. Those who complete the radical surgery will receive adjuvant platinum-based doublet chemotherapy for 1-4 cycles after surgery, followed by 17 cycles of maintenance therapy with Toripalimab, administered every 3 weeks on first day of each cycle.

Drug: Adjuvant immunotherapy

Interventions

Peroperative immunotherapy DRUG

Neoadjuvant phase: Toripalimab injection \[240 mg, administered on Day 1, Q3W (once every 3 weeks)\] + pemetrexed injection \[500 mg/m2, administered on Day 1, Q3W\] + carboplatin injection (AUC=5, administered on Day 1, Q3W) or cisplatin injection (75 mg/m2, administered on Day 1, Q3W) for 3 cycles; Adjuvant phase: Toripalimab injection \[240 mg, administered on Day 1, Q3W (once every 3 weeks)\] + pemetrexed injection \[500 mg/m2, administered on Day 1, Q3W\] + carboplatin injection (AUC=5, administered on Day 1, Q3W) or cisplatin injection (75 mg/m2, administered on Day 1, Q3W) for 1 cycles; Maintenanse phase: Toripalimab injection \[240 mg, administered on Day 1, Q3W (once every 3 weeks)\] for 13 cycles.

Perioperative immunotherapy

Neoadjuvant immunotherapy DRUG

Neoadjuvant phase: Toripalimab injection \[240 mg, administered on Day 1, Q3W (once every 3 weeks)\] + pemetrexed injection \[500 mg/m2, administered on Day 1, Q3W\] + carboplatin injection (AUC=5, administered on Day 1, Q3W) or cisplatin injection (75 mg/m2, administered on Day 1, Q3W) for 3 cycles;

Neoadjuvant immunotherapy

Adjuvant immunotherapy DRUG

Adjuvant phase: Pemetrexed injection \[500 mg/m2, administered on Day 1, Q3W\] + carboplatin injection (AUC=5, administered on Day 1, Q3W) or cisplatin injection (75 mg/m2, administered on Day 1, Q3W) for 1-4 cycles; Maintenanse phase: Toripalimab injection \[240 mg, administered on Day 1, Q3W (once every 3 weeks)\] for 17 cycles.

Adjuvant immunotherapy

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Aged 18-75, of either gender;
• Subjects with resectable stage II-IIIA non-small cell lung cancer (according to the AJCC 8th edition), EGFR wild type, and no ALK rearrangement, confirmed by histology or pathology;
• ECOG PS score of 0-1;
• There are measurable lesions according to RECIST 1.1;
• Expected survival duration ≥ 3 months;
• Main organ functions are normal (14 days before enrollment)
• According to the surgeon's assessment, the total lung function is capable of withstanding the proposed lung resection surgery;

You may not qualify if:

• Individuals known to be allergic to recombinant humanized anti-PD-1 monoclonal antibody drugs and their components;
• Currently participating in and receiving other research treatments;
• Previously received systemic treatment for resectable stage II-III non-small cell lung cancer, including systemic chemotherapy, targeted therapy, immunotherapy, etc;
• Patients with active tuberculosis (TB) who are currently undergoing anti-tuberculosis treatment or have received such treatment within the previous 1 year prior to screening;
• Uncontrollable or symptomatic hypercalcemia (\>1.5 mmol/L calcium ion or calcium \>12 mg/dL or corrected serum calcium \>ULN);
• Clinically, there is uncontrolled active infection, including but not limited to acute pneumonia;
• Uncontrollable severe epileptic seizures or superior vena cava syndrome;
• Previously or currently suffering from other malignant tumors (excluding non-melanoma basal cell carcinoma or squamous cell carcinoma of the skin, breast/cervical carcinoma in situ, superficial bladder cancer, and other carcinoma in situ that have undergone radical treatment with no evidence of disease recurrence);
• Patients with interstitial pneumonia, history of idiopathic pulmonary fibrosis, organizing pneumonia (such as bronchiolitis obliterans), drug-induced pneumonia, idiopathic pneumonia, evidence of active pneumonia found during chest CT scan screening, or other moderate to severe pulmonary diseases that seriously affect lung function;
• Known human immunodeficiency virus (HIV) infection (known HIV antibody positive);
• Having severe cardiovascular diseases, such as New York Heart Association (NYHA) class 2 or above heart failure, unstable angina pectoris, unstable arrhythmia, myocardial infarction or cerebrovascular accident occurring within 6 months before enrollment;
• Within 2 years prior to the commencement of the study, having received systemic immunosuppressive medications (i.e., using corticosteroids or immunosuppressive drugs) due to any active autoimmune disease;
• Subjects who received live virus vaccine within 4 weeks before the study began;
• Patients who have previously received allogeneic stem cell or solid organ transplantation;
• Pregnant or lactating women, or women who may become pregnant, who test positive for pregnancy before their first medication, or patients who are capable of bearing children but are unwilling to accept contraceptive measures, or whose sexual partners are unwilling to accept contraceptive measures;

Sponsors & Collaborators

• Fudan University: lead

Study Sites (1)

Fudan University Shanghai Cancer Center

Shanghai, 200032, China

Location

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 21, 2026
• First Posted: April 28, 2026
• Study Start: May 1, 2026
• Primary Completion (Estimated): May 1, 2030
• Study Completion (Estimated): May 1, 2032
• Last Updated: April 28, 2026

Record last verified: 2026-04

Data Sharing

• IPD Sharing: Will not share

Locations

CN (1)